Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LETI AT4 is a specialized dermo-cosmetic product line developed by Leti Pharma for the management and daily care of atopic, dry, and sensitive skin. The formulation is designed to address the four main signs of atopic skin: restoring the skin barrier, protecting against external aggressors, balancing the skin microbiota, and relieving itching and irritation. Key components typically include ceramides and essential fatty acids (such as linoleic acid) to repair the lipid barrier, polidocanol for its antipruritic properties, and specific prebiotics or peptidoglycans that help prevent the overgrowth of *Staphylococcus aureus*, a common pathogen in atopic dermatitis. It is available in various forms, including creams, body milks, and bath gels, and is suitable for infants, children, and adults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LETI AT4.